Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) is reporting third quarter financial results on Tuesday 27th October 2020, after market close.
According to analysts surveyed by Thomson Reuters, RARE is expected to report 3Q20 loss of $ 1.27 per share from revenue of $ 53.89 million.
For the full year, analysts anticipate top line of $ 209.26 million, while looking forward to loss of $ 4.39 per share bottom line.
Previous Quarter Performance
Ultragenyx Pharmaceutical Inc. unwinded loss for the second quarter of $ 1.12 per share, from the revenue of $ 61.71 million. The quarterly revenues improved 155.53 percent compared with the same quarter last year. The consensus estimates are loss of $ 1.54 per share from $ 39.12 million in revenue. The bottom line results beat street analysts by $ 0.42 or 27.27 percent, at the same time, top line results outshined analysts by $ 22.59 million or 57.75 percent.
Stock Performance
Shares of Ultragenyx Pharmaceutical Inc. traded up $ 1.16 or 1.26 percent on Friday, reaching $ 93.06 with volume of 248.60 thousand shares. Ultragenyx Pharmaceutical Inc. has traded high as $ 94.61 and has cracked $ 90.57 on the downward trend
According to the previous trading day, closing price of $ 93.06, representing a 187.28 % increase from the 52 week low of $ 31.99 and a 7.41 % decrease over the 52 week high of $ 99.25.
The company has a market capital of $ 5.64 billion and is part of the Healthcare sector and Biotechnology industry.
Recent Analyst recommendations
- On 15th October 2020, maintained by Bank of America at Buy rating, with $ 107.00 target price.
- On 13th October 2020, maintained by Morgan Stanley at Overweight rating, with $ 89.00 target price.
Conference Call
Ultragenyx Pharmaceutical Inc. will be hosting a conference call at 5:00 PM eastern time on 27th October 2020, to discuss its 3Q20 financial results with the investment community. A live webcast with presentations will be available on the Internet by visiting the Company website www.ultragenyx.com
Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in the United States. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia; and Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII. The company is also developing small-molecule pipeline comprising UX007, a synthetic triglyceride for the treatment of long chain fatty-acid oxidation disorders, which is a set of rare metabolic diseases that prevents the conversion of fat into energy; and gene therapy pipeline consisting of DTX301, an adeno-associated virus 8 gene therapy product candidate for the treatment of patients with ornithine transcarbamylase, as well as DTX401, an AAV8 gene therapy clinical candidate for the treatment of patients with glycogen storage disease type Ia.
